(Q42962563)

11 November 2017

Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients (English)

1 reference

11 November 2017

1 reference

Takeshi Ueda

1

1 reference

11 November 2017

Yusuke Imamura

2

1 reference

11 November 2017

Atsushi Komaru

3

1 reference

11 November 2017

Satoshi Fukasawa

4

1 reference

11 November 2017

Tomokazu Sazuka

5

1 reference

11 November 2017

Takahito Suyama

6

1 reference

11 November 2017

Yukio Naya

7

1 reference

11 November 2017

Naoki Nihei

8

1 reference

11 November 2017

Tomohiko Ichikawa

9

1 reference

11 November 2017

Masayuki Maruoka

10

1 reference

11 November 2017

23 July 2010

1 reference

International Journal of Urology

11 November 2017

1 reference

11 November 2017

17

1 reference

11 November 2017

811-815

1 reference

11 November 2017

9

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

11 November 2017

1 reference

Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2010.02604.X

10.1111/J.1442-2042.2010.02604.X

21 January 2018

Identifiers

DOI

1 reference

11 November 2017

1 reference